Search This Blog

Friday, December 5, 2025

Trump to tour nation with economic pitch as Dems hone MAAA ‘affordability’ attack

 President Trump got a rosy report Friday showing that consumer sentiment increased for the first time in five months, with voters feeling better about inflation and their personal finances as he prepares to tour the nation arguing he’s making economic progress.

Still, Dems are racing to make the midterm elections squarely about MAAA (Make America Affordable Again), contrasting Trump’s fancy White House ballroom renovations with adults priced out of the housing market and more.

Trump is pushing back by hitting the road to talk about his economic agenda, floating tariff rebates and 50-year mortgages.

He will kick off his economics-focused tour at a casino in northeastern Pennsylvania Tuesday, where he is expected to tout lower gas prices, his role securing $100 billion in energy and artificial intelligence investments for the Keystone State and his approval for Japanese investment in US Steel.

Trump reportedly is considering a second stop this month before hitting the road again in January.

President Trump will hit the road next week to tout his economic message after accusing Democrats of a “con job” attacking him on affordability issues.REUTERSThe president has taken to calling the term “affordability” a Democratic “con job” — pointing to inflation that’s lower on average than under former President Joe Biden while acknowledging the need to increase electricity production as prices surge due to AI data centers.

Although he ran for office promising to “make America affordable again” — in a twist on his Make America Great Again mantra — Democrats have now seized upon the phrase as they prepare a campaign strategy going into the November congressional elections.

Senate Minority Leader Chuck Schumer (D-NY) and House Minority Leader Hakeem Jeffries (D-NY) have devised a campaign strategy under that banner to push messaging on  health care, housing, food and energy prices, Axios first reported.

Schumer on Thursday posted a video montage on Instagram on Trump campaigning last year on making America “affordable” spliced with recent clips of Trump calling affordability a “Democrat hoax.”

The word “affordability” emerged as the go-to explanation, supported by polling, for Republicans’s election wipeouts in New Jersey, Virginia and New York City last month — with even conservatives admiring the disciplined messaging of the victorious Democrats in those contests.

Senate Minority Leader Chuck Schumer and House Minority Leader Hakeem Jeffries plan to campaign next year on a Make America Affordable Again platform.AP

Trump has sought to argue that he’s in the process of improving economic conditions — and the bump in consumer confidence, measured by the University of Michigan, is welcome news, showing less fear about future inflation.

In a likely preview of his remarks last week, Trump told his Cabinet Tuesday that “the word affordability is a Democrat scam. They say it and then they go on to the next subject, and everyone thinks, ‘Oh, they had lower prices.'”

Treasury Secretary Scott Bessent noted at the meeting that Trump’s signature first-year bill will reduce taxes on overtime, tips, Social Security benefits and allowing for deductions for domestic car loan interest — with those changes kicking in next year.

“The best way to address the affordability crisis is to give Americans more money in their pockets, which is what this bill has done,” Bessent said.

Later that day, Trump hosted an event celebration the looming launch of “Trump accounts” for newborns, which will be seeded with a $1,000 investment per child.

And the president has pushed for further perks for Americans, including a request for Congress to approve up to $2,000 tariff rebates from tariff revenue, if the Supreme Court upholds the duties in a pending case.

It’s unclear if the tariff rebate can pass due to Democratic opposition to the tariffs. Republican leaders shot down a late-2020 plan by Trump to issue similarly sized stimulus checks.

The 50-year mortgage idea, meanwhile, could lower monthly housing costs, though it always would result in slower accumulation of equity, and faces an uncertain path forward.

Treasury Secretary Scott Bessent noted Tuesday that tax breaks for tips, overtime, Social Security and car loan interest will soon kick in for Americans.YURI GRIPAS/POOL/EPA/Shutterstock

“Trump’s done a lot on his own — as much as possible and then some given the 60-vote threshold in the Senate — and he’s reasserted American leadership on the world stage. But, domestically, many voters, including within his own coalition, don’t know what’s being done or don’t think enough is being done,” said Michigan Republican strategist Dennis Lennox.

“They’re hearing constant headlines about white-collar job losses from AI. They don’t yet feel the full impact of declining inflation. And when they look at their paychecks, wages haven’t risen as quickly as they expected. The disconnect between what the administration is advancing and what voters are feeling in real time is driving much of the current frustration.”

Lennox said “the off-year and special elections were a wake-up call.”

“When you look at the generic ballot polling question and the swing Democrats were able to generate, it’s clear Republicans need to get it together,” he said. “2026 won’t be a persuasion election — it will be another turnout election. And the simple reality is that Trump drives turnout.”

Defending his record, Trump has for weeks noted his recent efforts to lower prescription drugs prices and the fact that egg prices and mortgage rates are down significantly since he took office.

He also has touted his tariffs as safeguarding American manufacturing jobs, though he recently lowered levies on bananas and coffee and beef to address rising trends.

But Democrats note that voters still rank economic concerns at their top issue as the Consumer Price Index remains stubbornly elevated at a 3% annual rate.

“He’s lowering tariffs on bananas, but consumers want to throw tomatoes at him. Democrats will have a lot of tomatoes to throw,” said a source familiar with the congressional Democratic campaign plans.

The source said Democrats intend to use “Trump’s own words” from last year’s campaign against him.

https://nypost.com/2025/12/05/us-news/trump-to-tour-nation-with-economic-pitch-as-dems-hone-maaa-affordability-attack/

Watch: Biden Called For Strike Force To Crush Drug Cartels In 1989!

 by Steve Watson via Modernity.news,

Democrats are melting down over Trump’s targeted strikes on narco-terrorists, yet a freshly resurfaced clip shows Joe Biden demanding the same aggressive action decades ago, proving their opposition is pure partisan sabotage as cartel poison floods America unchecked.

A 1989 C-SPAN clip of then-Senator Joe Biden has gone viral amid the Trump administration’s boat strikes on drug runners, highlighting the glaring double standard from Democrats who now baselessly cry “war crimes” over actions Biden once championed.

In the speech, Biden urged, “Let’s go after the drug lords where they live with an international strike force. There must be no safe haven for these narco-terrorists …”

What changed? Under Biden’s presidency, fentanyl deaths skyrocketed, with cartels controlling swaths of the border and trafficking exploding to record levels. Now, as Trump delivers on promises to hit back hard, Dems side with the traffickers out of sheer Trump derangement.

The clip, from a February 7, 1989, Senate hearing on crime and drugs, shows Biden pushing for swift, severe punishment of dealers and international operations to dismantle cartels before they infiltrate the U.S. 

He emphasized, “We have to join together to ensure that drug dealers are punished swiftly surely and severely.”

This echoes Trump’s designation of cartels as foreign terrorist organizations, a move Biden never pursued despite his tough talk.

Fast-forward to 2025, and Trump’s team is executing precision strikes on vessels linked to Venezuela’s Maduro regime and cartel operations, destroying drug cargoes and neutralising threats in the Caribbean.

Trump security advisor Stephen Miller blasted Democrats Wednesday for their twisted priorities in an explosive interview.

Miller declared, “This is the first time I can EVER think where a major political party has sided with narco-trafficking, murdering, terrorist SCUM!”

He added, “A Democrat says ‘oh, there’s no such thing as a narco-terrorist. They’re just narco-persons!’ ISIS and these narco-terrorists in our hemisphere use the same tactics. They use r*pe as a weapon. They skin people alive. They cut off their heads. They burn them to death!”

Miller further asserted “We’re not going off running around the Middle East trying to ‘build democracies’ in caves and deserts and in distant sands that have never known democracy.”

“We’re using the military to protect American security, American prosperity, American lives right here where we live, where our children live!” he urged.

Democrats, meanwhile, are inciting military discord while soft-pedaling cartel savagery. As we covered earlier, Virginia Sen. Mark Warner echoed seditious calls on MSNBC, stating “the uniformed military may help save us from this president.”

Warner ranted, “I’m going to want to get answers on what did Pete Hegseth order? Why haven’t we seen the whole unedited video if there’s nothing inappropriate here? You could have cleared this up without the admiral coming in. He’s got a great reputation, I respect him. I want to get the truth. And I’m not sure we’ve had the truth from Hegseth yet.”

Fresh reporting dismantles media smears. The New York Times revealed Hegseth authorized a Sept. 2 strike “to kill the people on the boat, destroy the vessel, and eliminate its drug cargo,” but it “did not specifically address what to do if a first missile failed to fully accomplish these goals, and it was not based on surveillance showing at least two survivors after the initial blast.”

White House press secretary Karoline Leavitt clarified Hegseth “authorized Adm. Frank M. Bradley to conduct kinetic strikes, ensuring the boat was destroyed and the threat eliminated.”

In addition, ABC’s Martha Raddatz provided key updates on ‘World News Tonight’, noting  “According to a source familiar with the incident, the two survivors climbed back on to the boat after the initial strike. They were believed to be potentially in communication with others, and salvaging some of the drugs.”

Raddatz added, “Because of that, it was determined they were still in the fight and valid targets.”

This confirms the strikes followed rules of engagement, with legal oversight—completely debunking Dem hysteria.

https://www.zerohedge.com/political/watch-biden-called-strike-force-crush-drug-cartels-1989

"Widespread Misconduct": All Beneficiaries Of Largest DEI Program To Surrender Financial Records

 The Daily Wire has learned that the Small Business Administration has ordered all 4,300 firms in its 8(a) "socially disadvantaged" program, which receive no-bid federal contracts, to turn over their financial records, including general ledgers, bank statements, payroll files, subcontracting agreements, and other internal documents, by January 5 or face removal from the program.

SBA's crackdown on one of Washington's oldest DEI initiatives follows mounting evidence that some 8(a) firms have become a major pipeline for fraud, pass-through schemes, and artificially inflated contract costs.

Late last month, Peter Schweizer, president of the Government Accountability Institute and the investigative journalist who broke the Clinton Cash corruption story, published a report exposing the cronyism and corruption inside the 8(a) program, where pass-through firms handed bidless contracts on silver platters while quietly outsourcing the real work to major consulting companies.

"For years, DC insiders have exploited a federal DEI contracting program that provides windfalls to Beltway elites. This open secret isn't about helping the downtrodden; it's about bagging no-bid paydays. The SBA's 8(a) program is long overdue for reform," Schweizer wrote on X.

There was also a recent U.S. Treasury Department investigation into $9 billion in small-business contracting, amid alarming concerns from Treasury Secretary Scott Bessent and others about rampant fraud and abuse in preference-based programs. In other words, meritocracy will return under the Trump administration.

Everyone in the DC consulting world understands how the game works: set up a compliant 8(a) "small business," win the no-bid award, and let the big consulting firms do all the work.

8(a) was DC's best-kept secret - until journalist James O'Keefe blew the lid off the DEI program. O'Keefe went undercover and captured video of an individual linked to ATI Government Solutions bragging about keeping $65 million of a $100 million contract while subcontracting out the work.

Several firms, including ATI, have since been suspended. Native American tribes whose names were used in pass-through schemes are also under increasing scrutiny.

SBA Administrator Kelly Loeffler said there is mounting evidence that minority contracts had become "a pass-through vehicle for rampant abuse and fraud," especially after the Biden administration raised the target for contracts "set aside" for minorities from 5% to 15% of all contracting dollars.

"We're committed to thoroughly reviewing every federal contract, contracting officer, and contractor — while working alongside federal law enforcement," Loeffler said.

Such reports "have raised questions about widespread misconduct within the 8(a) Business Development Program, adding to years of credible concerns that the program designed to serve 'socially and economically disadvantaged' businesses has become a vehicle for institutionalized abuse at taxpayer expense," the SBA wrote in its letter to the 4,300 "disadvantaged" firms.

Schweizer hinted at the 8(a) reforms needed:

Last week... 

DEI mandates have proven to make the government more dysfunctional and more costly. It's time to end the madness and "Make Meritocracy Great Again."  

https://www.zerohedge.com/political/widespread-misconduct-trump-admin-orders-all-beneficiaries-nations-largest-dei-program

FDA chief says Biden administration withheld data on heart risk from Covid vaccines

 The Biden administration withheld data from the public on the risks of myocarditis from the Covid vaccine, Food and Drug Administration Commissioner Marty Makary claimed Thursday — a bold accusation that clashes with years of public statements from federal health officials.

“We have done more to study myocarditis and to go back and look at deaths of people, of children from the Covid vaccine,” Makary told NBC News in an interview. “Internal data submitted on myocarditis, we found that the Biden administration was sitting on data on myocarditis in young people, and it was not made public.”

Makary’s claim comes less than a week after Vinay Prasad, the FDA’s top vaccine regulator, told agency staff in a memo that an internal review found that at least 10 children died “after and because of receiving” the Covid shot. Prasad suggested — without evidence to support his claim — that the child deaths were tied to myocarditis.

Myocarditis, an inflammation of the heart muscle, is a known — but small — risk of the mRNA Covid vaccines from Pfizer and Moderna, information that federal agencies have discussed openly since 2021.

The FDA has not released its new findings publicly, nor has the agency published them in a peer-reviewed journal. On Wednesday, a dozen former FDA leaders issued a scathing denunciation of the new assertions.

The first signs of a possible myocarditis link to the shots emerged in March 2021, when reports from both the U.S. and Israel cited rare cases following Covid vaccination. Symptoms of the condition include shortness of breath, chest pain and a fluttering or pounding heart.

In May 2021 — around the same time Pfizer’s Covid shot was authorized for young teens — the Centers for Disease Control and Prevention’s vaccine safety group said it was reviewing reports of heart inflammation in young people.

A month later, in June, the CDC’s vaccine advisory group met publicly to discuss the possible side effect. During that meeting, health officials said there was a “likely association” between myocarditis and the vaccines but panel experts concluded the benefits of vaccination outweighed the risks.

Then on June 25, 2021, the FDA added a warning about a rare risk of myocarditis to the patient and provider fact sheets for Pfizer’s and Moderna’s Covid shots.

A senior federal health official who worked in the Biden administration called Makary’s claim “absurd” and said the comment would do “irrevocable harm” to public trust in the FDA.

“There was no pressure coming from the White House,” the official said. “No one told us not to report adverse events. No one told us to approve products.”

Since the Covid shots were first approved in late 2020, the official said, the federal government has held more than a dozen public meetings to review data on Covid vaccines and published several papers on the myocarditis risk.

Dr. Ofer Levy, who was a member of the FDA’s advisory group at the height of discussion around myocarditis, said the federal government posted data and briefing documents online that were available to any American.

“I certainly didn’t see any secret information or cover-up in my experience working with the FDA,” said Levy, also director of the Precision Vaccines Program at Boston Children’s Hospital. “We were broadcast live in real time, with public commentary, and I didn’t have access to any more information than any other American.”

“It was a pretty good process, not perfect, but a pretty good process that’s respected around the world,” he said.

Makary said Thursday that the agency’s new findings about child deaths stem from an investigation, “reaching out to the families, reviewing the autopsies.”

“These were kids who died immediately after getting the Covid shot,” he said. “They went into myocarditis, or other serious vaccine complications.”

“When a healthy kid immediately gets a Covid shot and then develops a string of complications that results in a cascade resulting in the child’s demise,” he said, “that’s causal until proven otherwise.”

Makary didn’t elaborate on key details, such as the children’s ages, medical histories or whether they’d been diagnosed with Covid. He didn’t indicate when the data would be made public.

“Our scientists are working on this, so they’re putting it together,” he said.

The FDA’s new claims don’t align with the available evidence on vaccine-associated myocarditis.

The highest risk has been seen in teen and young adult males, particularly within several days after receiving the second dose of the primary series of the mRNA vaccines.

A CDC report published in 2021 found rates were 40.6 cases per million second doses of mRNA Covid vaccines administered to males ages 12 to 29 and 2.4 cases per million second doses administered to males ages 30 and older.

https://www.nbcnews.com/health/health-news/fda-chief-biden-administration-covid-vaccine-heart-risk-data-rcna247440

Enrollment in Medicare's Diabetes Prevention Program Has Been 'Pathetic'

 by Cheryl Clark

When it launched in April 2018, the Medicare Diabetes Prevention Program (MDPP) was championed as a key way to save billions by keeping millions of at-risk beneficiaries from developing diabetes.

Some 16 million overweight or obese beneficiaries with prediabetes were estimated to be eligible for the program.

But after 6 years, only 9,015 patients had enrolled in the program, according to a report prepared for CMS.

Indeed, less than 1% of eligible beneficiaries have participated in the program, CMS acknowledged in its final Physician Fee Schedule rule this year.

Several physicians who have been strong advocates of weight reduction, diet, and exercise programs to delay or prevent progression to diabetes said they were shocked by the low turnout.

"Pathetic," is how David Nathan, MD, of Harvard Medical School and Massachusetts General Hospital in Boston, who led the original Diabetes Prevention Program research that showed such efforts worked, described the low participation.

It "suggests that the programs have not been widely advertised and/or implemented ... like having a party and no one shows up," Nathan told MedPage Today.

The original Diabetes Prevention Program trials showed a 58% reduction in diabetes development over the first 3 years, and after 20 years or more, a 24% reduction, he noted.

"Considering the costly consequences of diabetes (human and economic), diabetes prevention is an excellent investment," Nathan said.

The MDPP is composed of 22 sessions of exercise and diet educational workshops in non-clinical settings, led by trained coaches. A special approval process developed by the CDC enabled 357 healthcare organizations or community groups to offer the program.

The providers involved would be paid by Medicare -- as much as $768 per enrollee in 2024 -- if specific attendance and/or at least 5% to 9% weight reduction targets were met by participants. All of this would be at no cost to the participant.

However, the report commissioned by CMS found that Medicare had spent less than $1 million in payments to the providers for about 3,480 fee-for-service beneficiaries. The average pay per beneficiary was $283, well below the maximum of $768.

Many MDPP suppliers interviewed for the report critiqued the program. "Current CMS administrative processes make it difficult to focus on recruitment, as a good deal of staff time is dedicated to billing, submitting reports, and coding claims," the report stated. "One partner organization noted that the billing process is especially burdensome for small community-based organizations."

"Several suppliers also noted that the current level of reimbursement for the program does not cover the costs to run the program and requested that CMS consider increasing the reimbursement rate," it continued.

About 40 medical associations and health systems wrote a letter last year to House of Representatives members calling the low participation "striking considering more than half a million participate in the CDC's National DPP program when offered through their health plan or employer."

Nearly one in three adults ages 65 and older have diabetes, the letter noted, and treating its complications cost the U.S. $205 billion in 2022 -- most of it paid by Medicare.

Endocrinologist Athena Philis-Tsimikas, MD, corporate vice president of the Scripps Whittier Diabetes Institute in San Diego, which enrolled about 20 to 30 Medicare beneficiaries in its MDPP programs each year, also was surprised at the low enrollment.

She acknowledged to MedPage Today that "the billing side has been very difficult," with several detailed steps required to document attendance and weight loss milestones to receive Medicare's full reimbursement. Additionally, a health system is not always set up for this type of billing, making claims submissions difficult.

Philis-Tsimikas suggested other possible explanations. Sometimes, she said, providers don't order the blood tests necessary to document prediabetes, necessary to qualify beneficiaries for enrollment. There are other priorities during the clinical visit, "and they forget to order it."

"We are likely missing people who meet the criteria but may not be identified yet," because a prediabetes diagnosis of an HbA1c of 5.7% to 6.5% must be confirmed by a lab, she said.

She also suggested that certain Medicare provider networks may not include the health system-run MDPP, and may not have an incentive to refer a patient to an outside provider.

Or it could be that physicians just aren't aware of the program. The agency and the programs might try harder to reach people who are at risk through health fairs or other settings, she said.

Bottom line may be that organizations offering the program may not find it worth it, considering the costs of hiring and training coaches.

"People say, if you don't see your return on investment within 3 or 4 years, some don't really want to make the investment," Philis-Tsimikas said.

A key barrier for the MDPP just 2 years after it began was the COVID public health emergency in 2020, which discouraged in-person attendance. But CMS changed the rules in January 2021, so that new beneficiaries could attend online, and weigh-ins were allowed virtually.

CMS has made other rule modifications to increase participation, in some cases extending the relaxed COVID-era rules. Starting in 2024, any participant could receive the program virtually.

And while the MDPP initially was a 2-year program, new beneficiaries now can complete it in 1 year.

Another change allows beneficiaries to record their weight at home with a date-stamped photo of their scale's reading. Because some beneficiaries are unable to do that due to physical limitations, CMS allows weight documentation from an official medical record if it is obtained within 5 days of a scheduled MDPP session.

The March consultant's report found that half of the beneficiaries who did end up participating in the program received a referral from a primary care physician or specialist, often when the provider was informing the patient they have prediabetes. The report added that clinicians' influence "underscores the important role healthcare providers play in connecting beneficiaries with the program."

Philis-Tsimikas said the low enrollment numbers were "sad to hear, especially for something that has been demonstrated to be so successful, and can prevent the chronic complications, the comorbidities, all these things that we try so hard to prevent."

https://www.medpagetoday.com/primarycare/diabetes/118849

Novel Drug Reduced Proteinuria by 46% in IgA Nephropathy Trial

At the American Society of Nephrology Kidney Week meeting, interim results from the phase III ORIGIN 3 trial showed that investigational atacicept (Vera) led to a 46% reduction in proteinuria at 36 weeks in patients with immunoglobulin A (IgA) nephropathy.

In this MedPage Today video, Sagar Nigwekar, MD, of Massachusetts General Hospital in Boston, explains the mechanism of action, study design, and the agent's potential role in this setting.

 So another exciting development at the recent Kidney Week meeting was the publication of interim data from a phase III trial of atacicept in patients with IgA nephropathy. And this trial was also published in the New England Journal of Medicine.

So atacicept is a native human transmembrane activator and calcium-modulator and cyclophilin-ligand interactor, all abbreviated as TACI. And it's a TACI-Fc fusion protein that inhibits two cytokines, the APRIL [a proliferation-inducing ligand] cytokine as well as the BAFF [B-cell activating factor] cytokine.

And so in this study that was published, which is a phase III study of atacicept, the investigators planned a double-blind, multicenter, randomized, placebo-controlled trial, and they enrolled patients with a biopsy-confirmed IgA nephropathy, and assigned them in a 1:1 ratio to receive either atacicept at a dose of 150 mg once a week, administered subcutaneously by patients at home, or matching placebo. And very similar to the trial of sibeprenlimab, they also looked at the percentage change from baseline in the urinary protein-to-creatinine ratio (UPCR), but this was analyzed at week 36 in the atacicept trial. And they also evaluated the safety.

So in this experiment, the investigators included 203 patients in this interim analysis. And what they note is, at week 36, the percent reduction from baseline in the UPCR was around 46% in the atacicept group and around 7% in the placebo group. So again, pretty substantial difference between the two groups and clearly favoring the atacicept.

This agent was also well tolerated and overall the frequency of adverse events was pretty comparable between the atacicept group and the placebo group.

So I think this is another exciting development, and again, similar to the previous agent I mentioned, confirms the key role that these cytokines play in the pathogenesis of IgA nephropathy, and also how the very targeted, innovative treatments can modulate these cytokines by inhibiting them. And then of course, conferring the advantages to the patients with IgA nephropathy.

https://www.medpagetoday.com/meetingcoverage/kidneyweekvideopearls/118855